Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005815 · ClinicalTrials.gov registry record · Phase 1
Temozolomide and Thalidomide in Treating Patients With Stage III or Stage IV Melanoma
A Phase 1 study of Melanoma (Skin) and Intraocular Melanoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 1
- Study location
NCT00005815 is a Phase 1 study of Melanoma (Skin) and Intraocular Melanoma that has completed, run by Memorial Sloan Kettering Cancer Center. The trial reports 1 study location across 1 state.
The verdict
NCT00005815, a Phase 1 study of Melanoma (Skin) and Intraocular Melanoma, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1
- Study location
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Thalidomide may stop the growth of melanoma by stopping blood flow to the tumor. Combining chemotherapy with thalidomide may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness temozolomide plus thalidomide in treating patients who have stage III or stage IV melanoma that cannot be removed during surgery.
Conditions Studied
Interventions
- DRUG temozolomide
- DRUG thalidomide
Study Locations (1)
New York
- Memorial Sloan-Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-12 |
| Est. Completion | 2004-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005815
The ClinicalTrials.gov registry entry for NCT00005815 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Melanoma (Skin) appearing as the primary indexed condition, and to 2 interventions - of which temozolomide is the first listed.
NCT00005815 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00005815 about?
NCT00005815 is a clinical study titled "Temozolomide and Thalidomide in Treating Patients With Stage III or Stage IV Melanoma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Thalidomide may stop the growth of melanoma by stopping blood flow to the tumor. Combining chemotherapy with thalidomide may kill more tumor cells. PURPOSE: Phase I/II trial to st...
What is the current status of trial NCT00005815?
This trial is currently completed. It is a Phase 1 study. The study started on 1999-12. Estimated completion is 2004-08.
What conditions does trial NCT00005815 study?
This clinical trial studies the following conditions: Melanoma (Skin), Intraocular Melanoma.
What interventions are being tested in trial NCT00005815?
The interventions under investigation include: temozolomide (DRUG), thalidomide (DRUG).
Who is sponsoring clinical trial NCT00005815?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00005815 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma (Skin)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
RECRUITING · Phase 1
-
Vaccine Therapy in Treating Patients With Metastatic Melanoma
COMPLETED · Phase 1
-
Vaccine Therapy in Treating Patients With Melanoma
COMPLETED · Phase 1
-
Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma
COMPLETED · Phase 1
-
Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma
COMPLETED · Phase 1
-
Biological Therapy in Treating Patients With Metastatic Melanoma
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.